// App-Quantinova.ai

8500 : IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Heather A. Wakelee

Principal Investigators

  • Caicun Zhou

  • Tibor Csoszi

  • Ihor O. Vynnychenko

  • Oleksandr Goloborodko

  • Alexander Luft

  • Andrey Akopov

  • Alex Martinez-Marti

  • Hirotsugu Kenmotsu

  • Yuh-Min Chen

  • Antonio Chella

  • Shunichi Sugawara

  • Barbara J. Gitlitz

  • Elizabeth Bennett

  • Fan Wu

  • Jing Yi

  • Yu Deng

  • Mark McCleland

  • Enriqueta Felip

Medical Centers

  • Stanford Univeresity Medical Center, Stanford, CA

  • New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China

  • Jasz-Nagykun Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary

  • Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine

  • MI Zaporizhzhia Regional Clinical Oncological Dispensary, Zaporizhzhya, Ukraine

  • Leningrad Regional Clinical Hospital, St. Petersburg, Russia

  • Pavlov State Medical University, St Petersbury, Russian Federation

  • Medical Oncology Department, Breast Cancer Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan

  • Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital and Department of Medicine, National Yang-Ming University, Taipei, Taiwan, Unit of Pneumology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan

  • Genentech, Inc., South San Francisico, CA

  • Roche China

  • shanghai, China

  • Genentech, Inc., South San Francisico, CA

  • Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain

Locations

  • China

  • Hungary

  • Ukraine

  • Russia

  • Spain

  • Japan

  • Italy

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Atezolizumab

  • Gemcitabine

  • Vinorelbine

  • Pemetrexed

  • Docetaxel

  • Cisplatin

  • SP263

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02486718

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved